<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00804544</url>
  </required_header>
  <id_info>
    <org_study_id>R-08-383</org_study_id>
    <secondary_id>12967</secondary_id>
    <nct_id>NCT00804544</nct_id>
  </id_info>
  <brief_title>99mTc-MIBI SPECT/CT in Breast Malignancy</brief_title>
  <official_title>Tc-99m Sestamibi SPECT/CT for Prediction of the Response of Locally Advanced Breast Malignancy to Neoadjuvant Chemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lawson Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>University of Western Ontario, Canada</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Lawson Health Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      99mTc-SestaMIBI mammoscintigraphy (MMS) may be used in patients with locally advanced breast
      cancer (LABC) scheduled for neoadjuvant chemotherapy. MMS may be performed for 1) nodal
      staging of axillary lymph node metastases, 2) prediction of chemosensitivity or Pgp/MDR-1
      mediated chemoresistance, and 3) evaluation of efficacy to chemotherapy and radiation
      therapy.

      MMS is routinely performed with planar/SPECT imaging according to the Society of Nuclear
      Medicine and European Association of Nuclear Medicine guidelines.

      In this pilot study, an optimised acquisition protocol will be setup with SPECT/low-dose
      multislice CT in addition to planar imaging.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      99mTc-SestaMIBI is a lipophylic cation as many cytotoxic chemotherapy drugs (i.e.
      anthracyclines, inhibitor of topoisomerase II, antimicrotubule, vinca alkaloids, inhibitors
      of DNA replication) accumulating in the mitochondria of tumour cells. MIBI tumour uptake is
      related to viability and proliferation due to increased perfusion and increased
      energy-dependent metabolism.

      99mTc-SestaMIBI is a substrate for the glycoprotein P (Pgp) pump encoded by the multidrug
      resistance gene -1 (MDR-1). MIBI tumour uptake with no significant wash-out over time (&lt;45%
      at 3H) predicts a chemosensitivity with no Pgp/MDR-1 overexpression. MIBI efflux with no
      significant tumour uptake predicts efflux of chemotherapy drugs from the tumour cells related
      to Pgp/MDR-1 overexpression or to anti-apoptotic Bcl-2 overexpression. Early MIBI efflux (&lt;
      1H) may also be related to pro-apoptotic Bax overexpression.

      SPECT/CT will be used for anatomic localisation and and attenuation correction. CT from
      SPECT/CT is a low-dose (&lt; 2 mSv) multislice CT (4 slice). SPECT/CT will also be used for
      correction of image-degrading factors including collimator-detector-response compensation for
      resolution recovery, and scatter correction. SPECT/CT based absolute semi-quantification of
      MIBI uptake into primary tumour and lymph nodes (i.e. standardised uptake value or SUV) will
      also be performed.

      SPECT/CT optimised imaging will be compared to planar/SPECT conventional nuclear imaging for
      1) detection of MIBI-avid primary breast tumour and lymph node metastases, 2)
      semi-quantification of MIBI uptake (T/B, SUV, and %wash-out) into primary breast tumour and
      lymph node metastases, 3) prediction of chemosensitivity at baseline, 3) Evaluation of
      chemotherapy efficacy after the first course of chemotherapy (after 2 weeks) compared to
      clinical response and histo-pathological response.

      SPECT/CT mammoscintigraphy findings will be compared to clinical findings (palpation),
      radiological findings (mammography, US, MRI), and histo-pathological findings (Pgp/MDR-1
      expression) into tumours after surgery.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    4 patients have been enrolled into the pilot study. No complications reported. Another clinical
    trial has been designed.
  </why_stopped>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">January 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1- Nodal staging 2- Prediction of chemosensitivity 3- Evaluation of chemosensitivity</measure>
    <time_frame>1 year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Added-Value of integrated SPECT/Low-dose MultiSlice CT versus planar/SPECT imaging in mammoscintigraphy with 99mTc-SestaMIBI</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">4</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Mammoscintigraphy with SPECT-CT optimized 99mTc-MIBI imaging (experimental arm) will be compared to conventional planar imaging. Mammoscintigraphy results before and after chemotherapy and radiation therapy, will be compared to the histopathological results after surgery.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>SPECT/CT</intervention_name>
    <description>SPECT/Low-Dose MultiSclice CT</description>
    <arm_group_label>1</arm_group_label>
    <other_name>Integrated SPECT/CT; Hybrid imaging</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with histologically proven breast cancer

          -  Patients with locally advanced breast cancer (stages T2-4 N0-3 M0)

          -  Patients scheduled for neoadjuvant chemotherapy

          -  Patients scheduled for radical modified mastectomy

          -  Patients with no physical and/or psychological contraindications

          -  Patients with no recent nuclear medicine study using long-lived isotopes (i.e. 67Ga,
             111In, 131I) within the 48 hour preceding the mammoscintigraphy

        Exclusion Criteria:

          -  Patient with no histologically proven breast cancer

          -  Patients with early stage T1 breast cancer

          -  Patients who are not candidates for neoadjuvant chemotherapy

          -  Patients who are not surgical candidates

          -  Patients with physical and/or psychological contraindications

          -  Pregnant or breast feeding patients

          -  Patients with a recent nuclear medicine study using long-lived isotopes (i.e. 67Ga,
             111In, 131I) within the 48 hour preceding the mammoscintigraphy
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Irina Rachinsky, MD, MSc</last_name>
    <role>Principal Investigator</role>
    <affiliation>The UWO - LHSC - Department of Nuclear Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Albert A Driedger, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>The UWO -LHSC - Department of Nuclear Medicine</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Muriel Brackstone, MD</last_name>
    <role>Study Director</role>
    <affiliation>The UWO - LHSC - Department of General Surgery</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Francisco Perera, MD</last_name>
    <role>Study Director</role>
    <affiliation>The UWO - LHSC - Department of Medical Oncology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>South Street Hospital - Department of Nuclear Medicine</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 4G5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <link>
    <url>http://www.uwo.ca/</url>
    <description>The University of Western Ontario</description>
  </link>
  <reference>
    <citation>Moretti JL, Hauet N, Caglar M, Rebillard O, Burak Z. To use MIBI or not to use MIBI? That is the question when assessing tumour cells. Eur J Nucl Med Mol Imaging. 2005 Jul;32(7):836-42.</citation>
    <PMID>15902437</PMID>
  </reference>
  <reference>
    <citation>Spanu A, Chessa F, Sanna D, Cottu P, Manca A, Nuvoli S, Madeddu G. Scintimammography with a high resolution dedicated breast camera in comparison with SPECT/CT in primary breast cancer detection. Q J Nucl Med Mol Imaging. 2009 Jun;53(3):271-80. Epub 2008 Jul 4.</citation>
    <PMID>18596669</PMID>
  </reference>
  <reference>
    <citation>Maini CL, Tofani A, Sciuto R, Semprebene A, Cavaliere R, Mottolese M, Benevolo M, Ferranti F, Grandinetti ML, Vici P, Lopez M, Botti C. Technetium-99m-MIBI scintigraphy in the assessment of neoadjuvant chemotherapy in breast carcinoma. J Nucl Med. 1997 Oct;38(10):1546-51.</citation>
    <PMID>9379190</PMID>
  </reference>
  <reference>
    <citation>Takamura Y, Miyoshi Y, Taguchi T, Noguchi S. Prediction of chemotherapeutic response by Technetium 99m--MIBI scintigraphy in breast carcinoma patients. Cancer. 2001 Jul 15;92(2):232-9.</citation>
    <PMID>11466674</PMID>
  </reference>
  <reference>
    <citation>Del Vecchio S, Zannetti A, Ciarmiello A, Aloj L, Caracò C, Fonti R, Botti G, D'Aiuto G, Salvatore M. Dynamic coupling of 99mTc-MIBI efflux and apoptotic pathway activation in untreated breast cancer patients. Eur J Nucl Med Mol Imaging. 2002 Jun;29(6):809-14. Epub 2002 Mar 13.</citation>
    <PMID>12029556</PMID>
  </reference>
  <reference>
    <citation>Sciuto R, Pasqualoni R, Bergomi S, Petrilli G, Vici P, Belli F, Botti C, Mottolese M, Maini CL. Prognostic value of (99m)Tc-sestamibi washout in predicting response of locally advanced breast cancer to neoadjuvant chemotherapy. J Nucl Med. 2002 Jun;43(6):745-51.</citation>
    <PMID>12050317</PMID>
  </reference>
  <reference>
    <citation>Khalkhali I, Diggles LE, Taillefer R, Vandestreek PR, Peller PJ, Abdel-Nabi HH. Procedure guideline for breast scintigraphy. Society of Nuclear Medicine. J Nucl Med. 1999 Jul;40(7):1233-5.</citation>
    <PMID>10405150</PMID>
  </reference>
  <reference>
    <citation>Xu HB, Li L, Xu Q. Tc-99m sestamibi scintimammography for the diagnosis of breast cancer: meta-analysis and meta-regression. Nucl Med Commun. 2011 Nov;32(11):980-8. doi: 10.1097/MNM.0b013e32834b43a9. Review.</citation>
    <PMID>21956488</PMID>
  </reference>
  <reference>
    <citation>Schillaci O, Danieli R, Filippi L, Romano P, Cossu E, Manni C, Simonetti G. Scintimammography with a hybrid SPECT/CT imaging system. Anticancer Res. 2007 Jan-Feb;27(1B):557-62.</citation>
    <PMID>17348441</PMID>
  </reference>
  <reference>
    <citation>Goldsmith SJ, Parsons W, Guiberteau MJ, Stern LH, Lanzkowsky L, Weigert J, Heston TF, Jones E, Buscombe J, Stabin MG; Society of Nuclear Medicine. SNM practice guideline for breast scintigraphy with breast-specific gamma-cameras 1.0. J Nucl Med Technol. 2010 Dec;38(4):219-24. doi: 10.2967/jnmt.110.082271. Epub 2010 Nov 5.</citation>
    <PMID>21057112</PMID>
  </reference>
  <results_reference>
    <citation>Bombardieri E, Aktolun C, Baum RP, Bishof-Delaloye A, Buscombe J, Chatal JF, Maffioli L, Moncayo R, Mortelmans L, Reske SN. Breast scintigraphy: procedure guidelines for tumour imaging. Eur J Nucl Med Mol Imaging. 2003 Dec;30(12):BP107-14.</citation>
    <PMID>14989223</PMID>
  </results_reference>
  <verification_date>March 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 4, 2008</study_first_submitted>
  <study_first_submitted_qc>December 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 9, 2008</study_first_posted>
  <last_update_submitted>March 2, 2012</last_update_submitted>
  <last_update_submitted_qc>March 2, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lawson Health Research Institute</investigator_affiliation>
    <investigator_full_name>Irina Rachinsky</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Integrated SPECT/CT</keyword>
  <keyword>99mTc-sestMIBI</keyword>
  <keyword>Chemosensitivity</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

